ClinicalTrials.gg
CompletedNCT01114828Updated Mar 4, 2014Results posted

A Study to Investigate Pharmacodynamics and Pharmacokinetics of OPC-41061 in Patients With Hepatic Edema

A Phase 3 interventional study of OPC-41061 and OPC-41061 in Cirrhosis, sponsored by Otsuka Pharmaceutical Co., Ltd.. Completed at 1 site in Japan. Open to participants aged 20 Years to 80 Years. Per ClinicalTrials.gov, last updated 2014-03-04.

Primary conditionFibrosis(the registry's first term)UnverifiedIs this wrong?Fibrosis is a broad heading, used only when no more specific condition is named. No better condition is named, so the registry's term is kept.

Sponsored by Otsuka Pharmaceutical Co., Ltd. (part of Otsuka Holdings Co., Ltd.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
20 Years to 80 Years
Sex
All
01

Study summary

OPC-41061 at 3.75 mg/day or 7.5 mg/day will be orally administered once daily for 7 days to cirrhosis patients with ascites despite having received treatment with conventional diuretics and pharmacodynamics, pharmacokinetics, efficacy, and safety will be investigated.

02

Conditions studied

  • Cirrhosis

Browse trials for

Keywords

  • Cirrhosis
  • ascites
  • Tolvaptan
  • OPC-41061
03

In context

Fibrosis Unverified

1,271 studies on the registry are indexed under Fibrosis; 277 are open to participants now.

This study's enrollment of 40 is below the median of 63 across 841 interventional studies indexed under Fibrosis.

Browse Fibrosis studies →

Lead sponsor

Otsuka Pharmaceutical Co., Ltd. is the lead sponsor of 143 studies on the registry; 11 are open to participants now.

Compared within Fibrosis, the registry's first condition term, which may not be this study's main condition. Counted across the registry records on this site, refreshed daily. How we classify →

04

Who can participate

Ages eligible
20 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients judged as having cirrhosis based on previous imaging diagnosis (Definition of cirrhosis includes patients with collateral circulation due to chronic hepatic impairment)
  • Patients with ascites in whom the dose of existing diuretics cannot be increased due to risk of adverse drug reactions such as electrolyte abnormalities, or in whom sufficient therapeutic effect cannot be obtained with existing diuretics
  • Patients who have been receiving oral combination therapy with a loop diuretic and an anti-aldosterone agent from at least 7 days prior to receipt of , with a dose combination of either loop diuretic equivalent to furosemide 40 mg/day or higher plus spironolactone 25 mg/day or higher, or loop diuretic equivalent to furosemide 20 mg/day or higher plus spironolactone 50 mg/day or higher
  • Patients who are hospitalized or who can be hospitalized for the trial - Age 20 to 80 years inclusive
  • Patients capable of giving informed consent
  • Patients who, together with their partner, agree to use an appropriate method of until 4 weeks after the final trial drug administration

Exclusion criteria

Exclusion Criteria:

  • Patients with any of the following complications or symptoms:

    • Hepatic encephalopathy (hepatic coma of grade 2 or higher)
    • Hepatocellular carcinoma with imaging-diagnosed vascular infiltration into trunk or primary branch of portal vein, inferior vena cava, or trunk of hepatic vein
    • Endoscopic findings from screening examination or from within 30 days prior to screening examination indicating the need for new therapy for esophageal or gastric varices during the trial period
    • Repeated hemorrhoidal bleeding due to rectal varicose veins within 30 days prior to
    • Heart failure ( Class III or IV)
    • Anuria
    • Impaired urination due to urinary tract stricture, urinary calculus, tumor in urinary tract, or other cause
  • Patients with a history of any of the following disorders:

    • Cerebrovascular disorder within 30 days prior to informed consent
    • or idiosyncratic reaction to benzazepine derivatives (such as mozavaptan hydrochloride or benazepril hydrochloride) "
  • Morbidly obese patients with a (BMI: body weight (kg)/height (m)2) exceeding 35
  • Patients with sitting systolic blood pressure lower than 90 mm Hg
  • Patients with any of following abnormal clinical laboratory values at time of the screening examination: lower than 8.0 g/dL, total higher than 4.0 mg/dL, serum creatinine higher than 2.0 mg/dL, serum sodium higher than 147 mEq/L, or serum potassium higher than 5.5 mEq/L
  • Patients who are unable to take oral medication
  • Female patients who are pregnant, possibly pregnant, or breast-feeding, or who are planning to become pregnant
  • Patients who have used albumin preparations (therapeutic agents for hypoalbuminemia) or blood products containing albumin from within 7 days prior to informed consent
  • Patients who received any drug other than OPC-41061 within 30 days prior to informed consent
  • Patients who have previously received OPC-41061
  • Any patient who, in the opinion of the principle investigator or subinvestigator, is inappropriate for participation in the trial
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    3.75 mg

    Once-daily oral administration of OPC-41061

    Drug: OPC-41061

  • Experimental
    7.5 mg

    Once-daily oral administration of OPC-41061

    Drug: OPC-41061

Interventions

  • Once-daily oral administration of OPC-41061 at 3.75 mg after breakfast for 7 days

  • Once-daily oral administration of OPC-41061 at 7.5 mg after breakfast for 7 days

06

What researchers measure

Primary outcomes

  1. Body Weight

    Changes from baseline (day-1) for body weight at the end of treatment (LOCF) were calculated.

    Time frame: Bseline, Day 7 or at the discontined of treatment

Secondary outcomes

  1. Ascites Volume as Measured by CT

    Change from baseline (day-1) for ascites volume as measured by CT at the end of treatment (LOCF) were calculated.

    Time frame: Baseline, Day 7 or at the discontinued of treatment

07

Results

Posted Jan 31, 2014

Participant flow

Participant flow — Overall Study
Milestone3.75 mg7.5 mg
Started1921
Completed1617
Not completed34
Withdrew: Adverse event11
Withdrew: Lack of efficacy02
Withdrew: Protocol violation20
Withdrew: Withdrawal by subject01

Outcome measures

PrimaryBody Weight

Changes from baseline (day-1) for body weight at the end of treatment (LOCF) were calculated.

Time frame:
Bseline, Day 7 or at the discontined of treatment
Reported as:
Mean · kg
Body Weight
kgOPC-41061 3.75 mgOPC-41061 7.5 mg
Body Weight-1.14 ± 0.86-1.37 ± 2.05
SecondaryAscites Volume as Measured by CT

Change from baseline (day-1) for ascites volume as measured by CT at the end of treatment (LOCF) were calculated.

Time frame:
Baseline, Day 7 or at the discontinued of treatment
Reported as:
Mean · mL
Ascites Volume as Measured by CT
mLOPC-41061 3.75 mgOPC-41061 7.5 mg
Ascites Volume as Measured by CT-407.5 ± 545.8-514.0 ± 993.8

Adverse events

Collected over 7 days. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
3.75 mg—2/19 (10.5%)13/19 (68.4%)
7.5 mg—3/21 (14.3%)15/21 (71.4%)
Most frequent serious events
Most frequent serious events
Event3.75 mg7.5 mg
Hepatic EncephalopathyNervous system disorders1/192/21
Gastrointestinal Angiodysplasia HaemorrhagicCongenital, familial and genetic disorders1/190/21
Gastric Ulcer HaemorrhageGastrointestinal disorders1/190/21
AscitesGastrointestinal disorders0/191/21
Blood Potassium IncreasedInvestigations0/191/21
Pleural EffusionRespiratory, thoracic and mediastinal disorders0/191/21
Most frequent other events
Showing 10 of 45
Most frequent other events
Event3.75 mg7.5 mg
ThirstGeneral disorders3/197/21
Blood Pressure DecreasedInvestigations3/190/21
Skin ExfoliationSkin and subcutaneous tissue disorders3/191/21
NauseaGastrointestinal disorders2/191/21
VomitingGastrointestinal disorders2/190/21
PyrexiaGeneral disorders2/191/21
ExcoriationInjury, poisoning and procedural complications2/190/21
Blood Alkaline Phosphatase IncreasedInvestigations2/190/21
Blood Potassium IncreasedInvestigations2/190/21
Blood Urine PresentInvestigations2/191/21

Baseline characteristics

Age, Continuous
Age, Continuous(years)3.75 mg7.5 mgTotal
Mean67.3 ± 9.364.2 ± 10.465.7 ± 9.9
Age, Categorical
Age, Categorical(Participants)3.75 mg7.5 mgTotal
<=18 years000
Between 18 and 65 years71118
>=65 years121022
Sex: Female, Male
Sex: Female, Male(Participants)3.75 mg7.5 mgTotal
Female5813
Male141327
Region of Enrollment
Region of Enrollment(participants)3.75 mg7.5 mgTotal
Japan192140
08

Study locations

1 site
  • Tokyo, et al., Japan
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2010, a primary completion of Oct 2011 and a completion of Dec 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2014, 2 years 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 29, 2010
First posted
May 3, 2010
Start
Feb 2010
Primary completionActual
Oct 2011
CompletionActual
Dec 2011
Results first posted
Jan 31, 2014
Last update
Mar 4, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 4, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01114828
Responsible party
Sponsor
First posted
May 3, 2010
Start date
Feb 2010
Primary completion
Oct 2011
Completion
Dec 2011
Results posted
Jan 31, 2014
Last update
Mar 4, 2014

Study contacts

Katsuhisa Saito
study director · Department of Clinical Research and Development, Otsuka Pharmaceutical Co., Ltd.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tolvaptan

Start the discussion